CIDARA THERAPEUTICS, INC.
CIK 0001610618
Revenue (TTM)
$4.29M
+195.3% YoY
Q3 Nov 2025
Net Income (TTM)
−$148.42M
−640.6% YoY
Q3 Nov 2025
EPS Diluted (TTM)
−$8.86
−409.5% YoY
Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
-3,695.3%
Q3 Nov 2025
Net Margin
-3,456.4%
Q3 Nov 2025
Free Cash Flow (TTM)
−$63.3M
Q3 Nov 2025
Cash
$293.65M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
31.44M sh
Q3 Nov 2025
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.